Caseware UK (AP4) 2023.0.135 2023.0.135 2023-11-302023-11-30falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.falsetrue2022-12-0132500 - Manufacture of medical and dental instruments and supplies 72110 - Research and experimental development on biotechnology11false 13756461 2022-12-01 2023-11-30 13756461 2021-11-01 2022-11-30 13756461 2023-11-30 13756461 2022-11-30 13756461 c:Director2 2022-12-01 2023-11-30 13756461 d:CurrentFinancialInstruments 2023-11-30 13756461 d:CurrentFinancialInstruments 2022-11-30 13756461 d:CurrentFinancialInstruments d:WithinOneYear 2023-11-30 13756461 d:CurrentFinancialInstruments d:WithinOneYear 2022-11-30 13756461 d:ShareCapital 2023-11-30 13756461 d:ShareCapital 2022-11-30 13756461 d:SharePremium 2023-11-30 13756461 d:SharePremium 2022-11-30 13756461 d:RetainedEarningsAccumulatedLosses 2023-11-30 13756461 d:RetainedEarningsAccumulatedLosses 2022-11-30 13756461 c:OrdinaryShareClass1 2022-12-01 2023-11-30 13756461 c:OrdinaryShareClass1 2023-11-30 13756461 c:FRS102 2022-12-01 2023-11-30 13756461 c:AuditExempt-NoAccountantsReport 2022-12-01 2023-11-30 13756461 c:FullAccounts 2022-12-01 2023-11-30 13756461 c:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30 13756461 e:PoundSterling 2022-12-01 2023-11-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 13756461










GAMBIT BIO LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 NOVEMBER 2023

 
GAMBIT BIO LTD
REGISTERED NUMBER: 13756461

BALANCE SHEET
AS AT 30 NOVEMBER 2023

As restated
2023
2022
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
20,010
1

  
20,010
1

Creditors: amounts falling due within one year
 5 
(7,288)
-

Net current assets
  
 
 
12,722
 
 
1

Total assets less current liabilities
  
12,722
1

  

Net assets
  
12,722
1


Capital and reserves
  

Called up share capital 
 6 
1
1

Share premium account
  
19,999
-

Profit and loss account
  
(7,278)
-

  
12,722
1


Page 1

 
GAMBIT BIO LTD
REGISTERED NUMBER: 13756461

BALANCE SHEET (CONTINUED)
AS AT 30 NOVEMBER 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




T S MA
Director

Date: 27 August 2024

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
GAMBIT BIO LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

1.


General information

Gambit Bio Limited is a private company limited by share capital and incorporated in United Kingdom.
The registered office is 9th Floor 107 Cheapside, London, United Kingdom, EC2V 6DN.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.3

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.4

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance Sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2022 - 1).

Page 3

 
GAMBIT BIO LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

4.


Debtors

As restated
2023
2022
£
£


Other debtors
20,010
1

20,010
1



5.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
60
-

Accruals and deferred income
7,228
-

7,288
-



6.


Share capital

As restated
2023
2022
£
£
Allotted, called up and fully paid



1,036,270 (2022 - 1,000,000) Ordinary Shares shares of £0.000001 each
1.04
1.00


During the year 36,270 Ordinary shares of £0.000001 were issued for consideration of £19,999.28.


7.


Prior year adjustment

An adjustment was posted to correct the bank, other debtors and share capital to accurately reflect shares issued in the prior year and the associated consideration. There was no impact on the profit and loss.


8.


Controlling party

The company is controlled by the directors.


Page 4